Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
0.3546
+0.0188 (5.60%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Mersana Therapeutics Stock Forecast
MRSN's stock price has decreased by -90.57% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Mersana Therapeutics stock have an average target of 4.00, with a low estimate of 3.00 and a high estimate of 5.00. The average target predicts an increase of 1,028.03% from the current stock price of 0.35.
Analyst Consensus: Buy
* Price targets were last updated on Aug 27, 2024.
Analyst Ratings
The average analyst rating for Mersana Therapeutics stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Buy | 1 | 1 | 1 | 2 | 2 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 7 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Feb 6, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +1,310.04% | Aug 27, 2024 |
| Baird | Baird | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +746.02% | Aug 14, 2024 |
| JP Morgan | JP Morgan | Sell → Hold Upgrades $5 | Sell → Hold | Upgrades | $5 | +1,310.04% | Mar 19, 2024 |
| Wedbush | Wedbush | Hold → Buy Upgrades $2 → $7 | Hold → Buy | Upgrades | $2 → $7 | +1,874.06% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
30.44M
from 40.50M
Decreased by -24.83%
Revenue Next Year
25.18M
from 30.44M
Decreased by -17.29%
EPS This Year
-0.73
from -0.56
EPS Next Year
-0.66
from -0.73
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 55.7M | 44.9M | 43.6M | ||
| Avg | 30.4M | 25.2M | 20.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 37.4% | 47.6% | 73.1% | ||
| Avg | -24.8% | -17.3% | -16.9% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.34 | -0.19 | -0.56 | ||
| Avg | -0.73 | -0.66 | -0.76 | ||
| Low | -0.92 | -0.87 | -0.88 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.